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BACKGROUND: Type II cancers account for 10% of endometrial cancers but 50% of recurrence. Response rates to chemotherapy at
recurrence are poor and better prognostic markers are needed to guide therapy. CD151 is a small transmembrane protein that
regulates cell migration and facilitates cancer metastasis. High CD151 expression confers poor prognosis in breast, pancreatic and
colorectal cancer. The prognostic significance of tetraspanin CD151 expression in poor outcome endometrial cancers was evaluated,
along with oestrogen receptor (ER), progesterone receptor (PR), p53, human epidermal growth factor receptor -2 (HER-2), and CD
151 staining compared with a6b1, a3b1 integrins, and E-cadherin.
METHODS: Tissue microarray constructed from 156 poor outcome endometrial cancers, tested with immunohistochemistry and
staining correlated with clinicopathological data were used. A total of 131 data sets were complete for analysis.
RESULTS: Expression of CD151 was significantly higher in uterine papillary serous and clear cell carcinoma than in grade 3 endometrioid
carcinoma, sarcoma or carcinosarcoma (Po0.001). In univariate analysis, age, stage, histology type and CD151 were significant for
both recurrence free (RFS) and disease specific survival (DSS). In multivariate analyses, CD151 was significant for RFS and DSS
(P¼0.036 and 0.033, respectively) in triple negative (ER, PR and HER-2 negative) tumours (88/131). The HER-2, p53, ER and PR
were not prognostic for survival. There was strong concordance of CD151 with E-cadherin (98%), but not with a6b1 (35%), a3b1
staining (60%).
CONCLUSION: The CD151 is a novel marker in type 2 cancers that can guide therapeutic decisions. CD151 may have an important role
in tumourigenesis in some histology types.
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Endometrial carcinoma is the most common neoplasm of the
female genital tract in the United States and Europe with a
worldwide estimated incidence in 2008 of 287000 cases and 74000
deaths from the disease (Ferlay et al, 2010). Endometrial cancer
has increased by over 40% in the United Kingdom since 1993, to an
incidence of 7536 in 2007 and 1741 deaths in 2008. (Cancer
Research UK, 2010) This increase is attributed to increased life
expectancy, tamoxifen use and obesity (Bray et al, 2005).
Endometrial cancer can be divided into oestrogen-dependent
adenocarcinoma with endometrioid morphology (type I) and non-
oestrogen-dependent adenocarcinoma (type II) predominantly
with serous papillary or clear cell but also grade III endometrioid
morphology (Bokhman, 1983; Rose, 1996). Molecular alterations
involved in the development of endometrioid endometrial
carcinomas are different from those of non-endometrioid carci-
nomas (Lax and Kurman, 1997). Type I carcinomas show more
microsatellite instability, and mutations in the PTEN, K-RAS,
PIK3CA and b-catenin genes. Alterations of p53, STK15, p16,
E-cadherin and HER-2 are more frequently found in type II
cancers (Kohler et al, 1996; Risinger et al, 1998; Maxwell et al,
2001; Morrison et al, 2006).
Type I cancers are diagnosed at an early stage and have a good
prognosis with 495% 5-year survival. Although type II carcino-
mas only account for 10–20% of all endometrial malignancies
(Bansal et al, 2009), they are responsible for B50% of all relapses
(Carcangiu and Chambers, 1992, 1995; Levenback et al, 1992) and
a low 5-year, all stage, overall survival rate of 35% (Singh et al,
2008). Chemotherapy regimes in advanced stage and recurrent
endometrial cancer have been disappointing, with a meta-analysis
demonstrating a translated improvement in progression free
survival by 1 month (pooled OR) with a concomitant significant
impact on quality of life from intensive chemotherapy regimes
(Humber et al, 2005). Few markers exist that can provide useful
clinical guidance for decision making, particularly, as is usually the
case, where the tumour marks negative for oestrogen (ER) and
progesterone (PR) receptors.
CD151 is one of 33 proteins in the mammalian tetraspanin
superfamily, which has emerged as a key player in malignancy, the
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simmune system, during fertilisation and infectious disease
processes (Hemler, 2008). The CD151 is a widely expressed
transmembrane protein, which is abundantly present on the
surface of various types of normal epithelial cells that make contact
with the basement membrane. Tetraspanins have a key role in the
formation of tetraspanin-enriched microdomains (TERM or TEM),
which also contain a number of other transmembrane receptors
(e.g., integrins, receptors tyrosine kinases). Laminin-binding
integrins (i.e., a3b1, a6b1, a6b4, a7b1) are most commonly
associated with TEMs and it has been shown that tetraspanins
regulate integrin-dependent adhesion strengthening, cell spreading
and migration (Yanez-Mo et al, 1998; Sincock et al, 1999;
Lammerding et al, 2003). Integrin-tetraspanin complexes are critical
for regulating cell invasiveness and controlling intercellular interac-
tions, both of which have a critical role during the metastatic
progression (Stipp, 2010). In breast cancer, CD151 expression is
increased in patients with invasive ductal carcinomas and this
correlates with higher tumour grade and node metastasis.
Importantly, CD151 was found to be a significant marker for poor
outcome (Novitskaya et al,2 0 1 0 ;S a d e jet al, 2010). The CD151 has
also been validated as a significant prognostic marker of outcome in
lung and prostate cancers (Tokuhara et al, 2001; Ang et al, 2004).
In this study, we investigate a cohort of endometrial cancers,
characterised clinically by poor histological features and antici-
pated poor survival. The prognostic significance of CD151
expression was assessed and compared with clinicopathological
features and previously used markers ER, PR, p53 and HER-2 in
patients with poor outcome endometrial cancer. We also compared
expression of CD151 with its binding integrin partners –a6b1, and
a3b1, and with E-cadherin in the tissue microarray.
PATIENTS AND METHODS
Patients and specimen characteristics
Upon approval from the Southmead research ethics committee
(REC ref. 07/H0102/64), archived paraffin-embedded tissue blocks
were collected from all women who underwent treatment for
International Federation of Gynaecology and Obstetrics (FIGO)
stage IA–IV uterine cancers at the Gloucestershire NHS Founda-
tion Trust Hospitals between 1997 and 2002. Histology types grade
3 endometrial adenocarcinoma (G3 EEC), uterine papillary serous
cancer (UPSC), clear cell carcinoma (CC), carcinosarcoma
(MMMT) and sarcoma were selected. Clinicopathological informa-
tion and survival data were abstracted from a regional prospec-
tively collected clinical database held at the South West Public
Health Observatory (SWPHO; Bristol, UK). A total of 85.9% of
patients underwent total abdominal hysterectomy with bilateral
salpingo-oophorectomy and peritoneal washings, in some women
pelvic node sampling was performed if they had been recruited to
the ASTEC trial (Kitchener et al, 2009). This was consistent with
surgical practice in the United Kingdom, in the study time period.
Patients without gross peritoneal disease and lymphadenectomy
were staged according to the extent of uterine involvement.
Adjuvant platinum based chemotherapy or pelvic radiation was
given at the discretion of the multidisciplinary team according to
local guidelines. No patient received chemotherapy or radio-
therapy before surgery. Patients were kept under surveillance for 5
years, longer follow-up details were abstracted from hospital
records from other attendances. Clinical endpoints were survival
or death of disease or other causes or date of recurrence as
recorded in the hospital notes. Data were cross-referenced against
cancer registry data to ensure accuracy.
Tissue microarray construction
Hematoxylin- and eosin-stained slides of tumours were reviewed
to confirm original diagnosis and two separate representative areas
of tumour marked on a corresponding paraffin block. Tissue
biopsies of 0.6mm diameter were taken from each donor block
and mounted in a recipient block using a tissue array machine.
(Beecher Instruments, Sun Prairie, WI, USA) Cores were set at
1mm intervals, two cores per case, to decrease the risk of aberrant
results due to tumour heterogeneity. Completed array blocks were
sealed for 10min in a 601C oven. The tissue array was monitored
by hematoxylin- and eosin-stain and in case of lack of visible
tumour a duplicate biopsy processed.
Immunohistochemistry
The 4mm paraffin sections from the array blocks were used.
Mouse anti-CD151 monoclonal antibody (mAb) The NCL-CD151
(Novocastra, Newcastle, Upon Tyne, UK) was used at dilution 1:50
(Berditchevski et al, 1997). Positive and negative controls were
samples of breast cancer and normal breast, respectively. After
16h antigen retrieval with 1 1m M EDTA pH 8.0, 0.1% Tween 20
buffer, immunostaining was carried out using standard avidin-
biotin-peroxidase complex method in the Shandon Sequenza
Immunostaining Station. (Thermo Electron Corp. US, Waltham,
MA, USA).
Cell surface adhesion molecules goat anti-human a3 integrin
subunit (Santa Cruz, Santa Cruz, CA, USA, sc-6588, antibody
concentration 0.67mgml
 1; dilution 1:300), rabbit anti-human a6
integrin subunit (Santa Cruz, sc-10730, antibody concentration
0.5mgml
 1; dilution 1:400) and mouse anti-E-cadherin (clone
NCH-38, Dako (Copenhagen, Denmark), antibody concentration
0.1mgml
 1; dilution 1:2000) were used. The W-CAP TEC buffer
pH 8.0 (Bio-Optica Milano s.p.a, Milan, Italy) was used in three-
step preparation. Sections were quenched in 0.3% H2O2 in distilled
water before primary antibody incubation at 41C for 16h. The
R.T.U Vectastain Universal Quick kit (Vector laboratory, Burlin-
game, CA, USA), and Dako Real Envision DAB chromagen and
solution (product: K5007, Dako) were used to detect both a3b1 and
a6b1. Sections of ductal carcinoma in situ (with skin) were used as
a positive tissue control.
Antibodies to oestrogen receptor (ER) (1D5 clone, Dako, Code
M7047, total protein concentration 11.9gl
 1, dilution of 1:35),
progesterone receptor (PR) (PgR 636 clone, Dako, Code M3569,
dilution of 1:35) and p53 (D-07 clone, Dako, Code M7001, total
protein concentration 11.9gl
 1, dilution 1:50) were used. Heat
induced epitope retrieval was carried out using Antigen Access
Unit (A. Menarini Diagnostics, Workingham, UK). Dako Auto
Stainer universal platforms were used for staining.
The expression of HER-2 was evaluated in an accredited
laboratory using Pathway HER-2 (Clone CB11) on the BenchMark
XT automated system (Ventana Medical Systems Inc., Tucson, AZ,
USA) and HER-2 antibody: A0485 clone (polyclonal antibody,
Dako, HercepTest, dilution of 1:400) was used with known
positive and negative breast cancer cell cultures included as
controls.
Positive staining for CD151 was defined by crisp cytoplasmic
and partly membranous staining, ER and PR by clear nuclear
staining, p53 by unequivocal strong nuclear staining, HER-2 by
clear membranous staining; a3b1, a6b1 integrins by cytoplasmic
and membranous staining and E-cadherin by strong membranous
staining.
Evaluation of immunohistochemical staining
All markers were evaluated independently, using light microscopy
at  400 magnification by two pathologists blinded to the data on
at least two separate occasions. In event of intra-observer or inter-
observer variation a consensus score was decided after examina-
tion at a multi-headed microscope. CD151, ER, PR and p53 were
scored in a semi-quantitative manner incorporating both intensity
of staining and distribution. Staining intensity (I) was graded as 0
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s(no staining), 1 (weak), 2 (moderate), or 3 (strong). The
proportion (P) of cells (0–100%) with the observed staining
intensity was recorded. A score (histologic or H-score) was
determined as the product of the intensity and proportion using
the formula (H¼I P) (Budwit-Novotny et al, 1986; Katz et al,
1990; Wilder et al, 2004). H-score¼(1 percentage of cells stained
at intensity category 1)þ(2 percentage of cells stained at
intensity category 2)þ(3 percentage of cells stained at intensity
category 3). H-score between 0 and 300 was obtained where 300
was equal to 100% of tumour cells stained strongly. H-score X150
was considered positive for the above markers. HER-2 scores were
evaluated by a pathologist (GS) as per established guidelines
(Wolff et al, 2007). Cases were scored from 0–3 and considered
positive when 41.
Statistical analysis
Fisher’s exact test was used for association analyses of tumour
types or stages with proportion of positive expression. Survival
data were analysed with Kaplan–Meier estimator and Cox
proportional hazards model. A z-test was used to test statistical
significance of each coefficient in the model. Deaths due to causes
other than endometrial cancer were excluded from analyses of
disease specific survival (DSS) or recurrence free survival (RFS).
All statistical analyses were carried out using R (http://www.
r-project.org/). Two-sided P-values less than 0.05 were considered
statistically significant. The ‘REMARK’ criteria of the National
Cancer Institute were used in design, analysis and interpretation
(McShane et al, 2005).
RESULTS
A total of 156 patients that fitted the inclusion criteria were treated
in 1997–2002. Clinical and pathological features are summarised
in Table 1. Seventy-eight patients died during the observation
period, 60 related to endometrial cancer and 18 related to other
causes. A total of 64 adverse events were recorded, which included
recurrent disease as well as deaths related to endometrial
cancer. Three histological groups were formed for analysis:
G3 EEC¼group 1; USPCþCC¼group 2 and sarcomaþ
MMMTþmixed tumours¼group 3. Of 156 patients included in
this study, 131 patients (83.97%) had archived paraffin embedded
tissue and complete follow-up data available for analysis.
Mean follow-up time was 4.01 years (range, 0.01–11.79 years).
Mean all-stage-, all-histology- overall survival (OS) was 4.01 years
(range 0.01–11.79years), DSS (114 of 131) was 4.267 years (range
0.01–11.79) and RFS (114 of 131) was 4.108 years (range
0.01–11.79). Patients with low stage (I–II) had a DSS of 5.318
years whereas patients with advanced stage (III–IV) lived
significantly shorter with a DSS of 2.24 years (hazard ratio (HR)
4.373, CI 2.55–7.49, Po0.001) (Table 3).
Figure 1 shows immunohistochemistry with antibodies to
CD151, HER-2, E-cadherin, and a3b1, a6b1 integrin subunits.
CD151 scored positive in 98.5% of USPCþCC cases, but less than
50% of G3 EEC or sarcomaþMMMTþmixed group. CD151
expression was significantly raised in USPCþCC tumour types
compared with G3 EEC (Po0.001) and sarcomaþMMMTþ
mixed (Po0.001). Expression of CD151 was highest in ‘triple-
negative’ tumours as compared with the rest of the cohort
(Po0.001). A detailed analysis of CD151, HER-2, ER, PR and
p53 expression by stage and histology is presented in Table 2.
CD151 showed no specific association with tumour stages. HER-2
positivity (41) was seen in only eight cases (6.11%).
In univariate analyses age, stage, expression of CD151 and
histology type, specifically sarcoma/MMMT/mixed group, were
significant factors impacting on DSS and RFS (Table 3). Low
CD151 expression was associated with significantly worse DSS (HR
1.816, P¼0.02) and RFS (HR 1.773, P¼0.02) when compared with
strong expression, this is represented in Figure 2. HER-2, ER, PR
and p53 expression were not significantly associated with survival.
The association of the diminished expression of CD151 with
reduced DSS (HR 2.94, Po0.001) and RFS (HR 2.54, Po0.001) was
even stronger in the triple negative (ER, PR and HER-2-negative)
subgroup (n¼88). In multivariate analyses age, stage and tumour
type maintained significance. CD151 maintained prognostic
significance in multivariate analysis for the triple negative
subgroup (DSS, P¼0.033, RFS, P¼0.036) but not for the entire
cohort (Table 4). Oestrogen receptor, PR, p53 and HER-2 were not
significant factors influencing survival.
The a3b1, a6b1 and E-cadherin were also investigated in one
tissue microarray and compared with CD151 expression. Strong
staining with a6b1 integrin was seen in four cores, in 14 cores for
a3b1 strong staining and in 26 cores for E-cadherin staining. There
was strong concordance (98%) of CD151 and E-cadherin staining,
Table 1 Clinicopathological data
Clinical data Patients (n¼156)
Age, mean (s.d., range) 68.2 (11.4, 37–89)
FIGO stage, n (%)
I 87 (55.77)
II 14 (8.97)
III 35 (22.4)
IV 20 (12.8)
Histologic type, n (%)
G3 EEC 78 (50.0)
UPSC 33 (21.15)
Clear cell 9 (5.8)
MMMT 18 (11.5)
Sarcoma 14 (8.97)
Mixed histology 4 (2.6)
Myometrial invasion, n (%)
p50% 58 (37.2)
450% 94 (60.3)
Missing 4
Hysterectomy
Yes 134 (85.9)
No 22 (14.1)
Lymphnodes
Taken 32 (20.51)
Not taken 124 (79.49)
Chemotherapy, n (%)
Yes 28 (17.9)
No 128 (82.1)
Radiotherapy, n (%)
Yes 64 (41.0)
No 92 (59.0)
Outcome
Alive without disease 73 (46.8)
Alive with disease 4 (2.6)
Died of disease 61 (39.1)
Death of other causes 18 (11.5)
Observation time mean (range) 148 months (0.1–11.07 years)
Complete data for analysis 131 (83.97%)
Lost for follow-up or missing tissue-samples 25 (16.03%)
Abbreviations: G3 EEC¼grade 3 endometrioid endometrial carcinoma;
FIGO¼International Federation of Gynaecology and Obstetrics; MMMT¼malignant
mixed mullerian tumour; UPSC¼uterine papillary serous cancer.
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swith only 1 of 43 tumours showing discordance in staining (i.e.,
cores positive for CD151 were positive for E-cadherin staining and
cores negative for CD 151 were negative for E-cadherin staining).
Only 15 of 43 cores showed concordance with a6b1and CD151
staining (35%) and 26 of 43 cores (60%) showed concordance
between a3b1 and CD151 staining (Figure 1).
DISCUSSION
This is the first study to evaluate the staining and prognostic
significance of tetraspanin CD151 in endometrial carcinoma. We
selected tetraspanin CD151 as a marker based on studies in breast
cancer, which demonstrated its prognostic utility in a subgroup of
invasive ductal carcinomas (Sadej et al, 2009; Novitskaya et al,
2010). Our results show that CD151 is an independent marker for
DSS and RFS in poor outcome endometrial carcinoma by
univariate analysis and for a triple negative subgroup of patients
by multivariate analysis. CD151 is also differentially expressed,
with highest expression in the UPSC and CC histology types.
Contrary to our expectation, we found that high CD151 expression
is positively correlated with improved survival. Thus, this is the
first report, which suggests that expression of this tetraspanin
protein in tumours may prevent transition to a more malignant
phenotype.
A
C
E
GH
F
D
B
Figure 1 Immunohistochemistry with antibodies to CD151, HER-2, integrins a6b1, a3b1 and E-cadherin. A and B – CD151 ( 100 and  200,
respectively); C and D – E-cadherin ( 100 and  200, respectively); E and F – integrin a3b1( 100 and  200, respectively); G and H – integrin a6b1
( 100 and  200, respectively).
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sTable 2 Clinicopathological features of CD151, ER PR, p53 and HER-2 expression by immunohistochemistry
Patients n
CD151 positive
n (%)
ER positive
n (%)
PR positive
n (%)
P53 positive
n (%)
HER-2 positive
n (%)
Stage
I 71 45 (63.3) 12 (16.90) 6 (8.45) 15 (21.12) 3 (4.22)
II 14 5 (35.7) 2 (14.3) 0 3 (21.4) 2 (14.3)
III 28 12 (42.8) 3 (10.7) 2 (7.1) 9 (32.1) 1 (3.6)
IV 18 10 (55.5) 4 (22.2) 2 (11.1) 4 (22.2) 2 (11.1)
(I–II) 85 50 (58.8) 14 (16.5) 6 (7.1) 18(21.2) 5 (5.9)
(III–IV) 46 22 (47.8) 7 (15.2) 4 (8.7) 13 (28.3) 3 (6.5)
Histology
Group I 68 25(36.76) 15 (22.06) 3 (4.4) 13 (19.1) 3 (4.4)
USPC 31 30 (96.7) 6 (19.4) 4 (12.9) 11 (35.4) 4 (12.9)
CC 7 7 (100) 0 1 (14.3) 1 (14.3) 1 (14.3)
Sarcoma 13 4 (30.8) 0 0 5 (38.5) 0
MMMT 9 1 (11.1) 0 2 (22.2) 0 0
Tumours mixed histo 3 0 0 0 1 (33.3) 0
Group II 38 37 (97.4) 6 (15.8) 5 (13.2) 12 (31.6) 5 (13.2)
Group III 25 5 (20) 0 2 (8) 6 (24) 0
Abbreviations: CC¼clear cell carcinoma; ER¼oestrogen receptor; MMMT¼malignant mixed mullerian tumour; PR¼progesterone receptor; UPSC¼uterine papillary serous
sarcinoma. ER, PR, p53 and CD151 are regarded as positive when H-score X150. The HER-2 is regarded positive when score 41. Group I comprised of G3 EEC, group II
comprised of UPSC and CC, group III comprised of MMMT, sarcoma and mixed mesodermal tumours.
Table 3 Univariate analysis of DSS and RFS
DSS RFS
HR 95% CI P HR 95% CI P
Age 1.055 1.02–1.08 o0.001 1.056 1.03–1.08 o0.001
Stage (I, II vs III, IV) 4.373 2.55–7.49 o0.001 3.965 2.37–6.62 o0.001
Histology
a
Group II vs group I 1.069 0.55–2.067 0.84 1.056 0.56–1.96 0.86
Group III vs group I 2.926 1.58–5.40 o0.001 2.577 1.41–4.69 0.001
CD151 1.816 1.06–3.10 0.02 1.773 1.06–2.96 0.02
CD151 (in ER, PR and HER-2 negative tumours) 2.94 1.50–5.74 o0.001 2.541 1.37–4.71 0.008
HER-2 1.541 0.55–4.26 0.402 1.408 0.51–3.88 0.506
P53 1.283 0.71–2.32 0.409 1.112 0.62–1.99 0.72
ER 0.815 0.38–1.72 0.591 0.851 0.419–1.72 0.655
PR 0.962 0.34–2.66 0.94 0.864 0.31–2.38 0.77
Abbreviations: CI¼confidence interval; DSS¼disease specific survival; ER¼oestrogen receptor; HR¼hazard ratio; PR¼progesterone receptor; RFS¼recurrence free survival.
Univariate analysis of age was performed in a linear manner; therefore, there is no referent variable.
aUnivariate analysis of histology carried out with endometrioid histology as
reference. Significant P-values for CD151 are in bold.
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Figure 2 Kaplan–Meier survival curves demonstrating effect of CD151 expression on DSS and RFS in the entire cohort. For DSS, the hazard ratios of
CD151 greater than median is 1.816 (95% confidence interval 1.060–3.109, P¼0.02746) and for RFS is 1.773 (95% confidence interval 1.062–2.961,
P¼0.02647) indicating that there is a significant survival benefit in the group overexpressing CD151.
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sThe strengths of this study are the long duration of follow-up
and high numbers of poor prognostic types of tumours. Our
cohort includes G3 endometrioid endometrial cancers, which are
usually not included into type II endometrial cancers. However,
they fit the criteria in so far as they demonstrate more aggressive
behaviour and are of significantly poorer prognosis (58% 5 year
survival) than low-grade endometrioid cancers (Bokhman, 1983).
In addition, analyses of survival outcome between histological groups
I and II show no difference in RFS or DSS (data not shown).
Additionally we included sarcomas, carcinosarcomas and uterine
tumours of mixed histology for the same reason – they are also poor
prognosis tumours with currently no adjuvant treatment that has
shown to clearly improve survival (Sutton et al,2 0 0 0 ;D e n i a u d -
Alexandre et al, 2001; Weitmann et al, 2002; Giuntoli et al, 2003; Livi
et al,2 0 0 3 ;T o y o s h i m aet al,2 0 0 4 ) .A l t h o u g ht h et i s s u es e tc o n t a i n s
divergent histology types, clinically these tumours result in poor
outcome and justify being investigated together.
Increased expression of CD151 also correlates with advanced
tumour grades and poor prognosis in other tumours. Ang et al,
(2004) showed that overall survival was reduced in prostate cancer
tumours where CD151 was overexpressed . This was consistent with
findings in lung cancer (Tokuhara et al, 2001). In colon cancer,
changes in expression of CD151 appear to be more complex. An early
report has described that increased expression levels of this
tetraspanin correlated with a more advanced stage of the disease
(Zijlstra et al, 2008). However, a more recent study has found that
expression of CD151 protein was reduced in human colon cancers
compared with surrounding normal tissue, in which it is strongly
expressed on the basal and lateral surfaces of epithelial cells (Chien
et al, 2008). The authors hypothesised that intra-tumoural activation
of hypoxia-inducible factor 1 led to inhibition of CD151 expression
and this repressed the function of E-cadherin (Chien et al, 2008),
thereby dramatically reducing cell-to-cell adhesion and thus increas-
ing invasion and metastasis. Interestingly, it was also found that the
expression level of CD151 in the metastatic lesions was increased
when compared with primary colon cancer tissues.
Although the exact biochemical function of CD151 is still
unknown, evidence shows that it is involved in signal transduction
(Yauch et al, 1998; Zhang et al, 2001), cell adhesion (Hasegawa
et al, 1998), and motility (Testa et al, 1999). In relation to tumour
metastasis, experiments using anti-CD151 mAb have established
that this tetraspanin may contribute to an early step in the
formation of secondary metastatic lesions by mediating invasive-
ness of primary tumour cells into surrounding stromal tissues and
vascular intravasation (Testa et al, 1999). More recently, we have
shown that CD151 can also regulate recruitment of breast cancer
cells to the lungs and growth of the metastatic lesion (Sadej et al,
2010). Thus, tetraspanin CD151 may be involved in various aspects
of the metastatic cascade.
Although our results strongly suggest that CD151 may have an
important role in tumourigenesis in some histology types of
endometrial cancer, the mode of its action remains unknown.
Holcomb et al, (2002) examined E-cadherin in endometrial
carcinoma and found that papillary serous and clear cell
carcinomas show significantly reduced E-cadherin expression in
comparison with endometrioid tumours (P¼0.01). Thus, one
possibility might be that CD151 counteracts the metastatic
progression of endometrial cancer by stabilizing E-cadherin based
cell-cell interactions. In this regard, it is noteworthy that we found
a strong correlation in the expression levels of E-cadherin and
CD151 in cancer samples. Alternatively, CD151 may act through
laminin-binding integrins, its main molecular partners in tetra-
spanin microdomains, by strengthening interactions of endome-
trial cells with laminin components of the basement membrane.
Detailed immunohistochemical analyses of endometrial cancer
tissues will be necessary to address this issue in the future.
So far, treatment options in type II cancers are largely limited to
surgical- and/or chemotherapy regimen, which have not altered
the poor prognosis of these tumours.
There is an unmet clinical need for robust prognostic markers
that can help in guiding therapeutic decisions in these tumour
types, particularly at recurrence and at advanced stage. This study
suggests that, in patients with CD151 positive tumours, survival is
significantly better than those with CD151 negative tumours. This
could be highly clinically relevant as even in a triple negative
marker group, CD151 is highly prognostic of both DSS and RFS. A
larger prospective study of CD151 in this group of cancers is now
being established to confirm these findings. An enhanced under-
standing of the molecular basis of these tumours will also aid in the
development of novel, targeted therapies.
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